IRIS
SILVESTRIS, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.118
AS - Asia 4.818
EU - Europa 2.739
SA - Sud America 1.248
AF - Africa 165
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 1
Totale 24.101
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.929
SG - Singapore 2.363
BR - Brasile 1.102
CN - Cina 875
SE - Svezia 742
HK - Hong Kong 730
RU - Federazione Russa 586
VN - Vietnam 289
GB - Regno Unito 253
DE - Germania 216
IT - Italia 198
FR - Francia 189
IN - India 142
BE - Belgio 110
CA - Canada 90
FI - Finlandia 86
AR - Argentina 59
UA - Ucraina 59
CI - Costa d'Avorio 58
BD - Bangladesh 56
MX - Messico 56
TR - Turchia 56
ID - Indonesia 53
PL - Polonia 45
ZA - Sudafrica 42
IQ - Iraq 40
JP - Giappone 40
CZ - Repubblica Ceca 39
ES - Italia 36
AT - Austria 29
VE - Venezuela 29
NL - Olanda 23
PK - Pakistan 18
AE - Emirati Arabi Uniti 17
EC - Ecuador 17
CO - Colombia 15
IE - Irlanda 15
IR - Iran 15
BG - Bulgaria 14
LT - Lituania 14
UZ - Uzbekistan 14
IL - Israele 13
NP - Nepal 11
ET - Etiopia 9
KE - Kenya 9
MA - Marocco 9
RS - Serbia 9
SA - Arabia Saudita 9
CH - Svizzera 8
HR - Croazia 8
KR - Corea 8
EG - Egitto 7
PT - Portogallo 7
TN - Tunisia 7
CL - Cile 6
CR - Costa Rica 6
DZ - Algeria 6
JO - Giordania 6
PY - Paraguay 6
QA - Qatar 6
RO - Romania 6
AL - Albania 5
AZ - Azerbaigian 5
BO - Bolivia 5
DK - Danimarca 5
HN - Honduras 5
HU - Ungheria 5
JM - Giamaica 5
KW - Kuwait 5
KZ - Kazakistan 5
LV - Lettonia 5
NO - Norvegia 5
PA - Panama 5
PE - Perù 5
TT - Trinidad e Tobago 5
AU - Australia 4
BH - Bahrain 4
GE - Georgia 4
MY - Malesia 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
AM - Armenia 3
AO - Angola 3
BB - Barbados 3
BW - Botswana 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
EE - Estonia 3
LB - Libano 3
LU - Lussemburgo 3
LY - Libia 3
MT - Malta 3
NG - Nigeria 3
NI - Nicaragua 3
SN - Senegal 3
GR - Grecia 2
KG - Kirghizistan 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
NR - Nauru 2
Totale 24.061
Salva come PNG Salva come JPEG
Città #
Fairfield 2.057
Ashburn 1.779
Chandler 1.769
Singapore 1.269
Woodbridge 1.034
Seattle 913
Cambridge 908
Houston 837
Hong Kong 723
Wilmington 652
Nyköping 569
Ann Arbor 397
Beijing 384
Lawrence 245
Dallas 242
Roxbury 230
Los Angeles 197
New York 162
Des Moines 146
The Dalles 120
Brussels 108
Paris 108
Columbus 104
San Diego 101
Inglewood 92
Brooklyn 91
Ho Chi Minh City 90
Munich 90
Dearborn 89
São Paulo 88
Council Bluffs 83
Santa Clara 83
Jacksonville 79
Moscow 75
London 72
Hanoi 65
Abidjan 58
Pune 55
San Jose 55
Bari 52
Boardman 50
Jakarta 44
Chicago 42
Warsaw 41
Nanjing 40
Rio de Janeiro 39
Helsinki 37
Tokyo 37
Buffalo 34
Washington 34
Phoenix 33
Turku 29
Chennai 28
Montreal 27
Brno 26
Denver 26
Edinburgh 26
San Mateo 26
Atlanta 25
Johannesburg 25
San Francisco 25
Brasília 24
Ankara 23
Belo Horizonte 23
Falls Church 23
Frankfurt am Main 23
Orem 23
Princeton 23
Stockholm 23
Dong Ket 22
Mexico City 22
Toronto 22
Poplar 21
Porto Alegre 21
Jinan 20
Ruvo Di Puglia 20
Vienna 20
Boston 19
Shanghai 18
Monmouth Junction 17
Norwalk 17
Da Nang 16
Düsseldorf 16
Guangzhou 16
Hefei 16
Amsterdam 15
Augusta 15
Baghdad 15
Dublin 15
Falkenstein 15
Rome 15
Campinas 14
Mumbai 14
Charlotte 13
Curitiba 13
Grafing 13
Jiaxing 13
Marseille 13
Nuremberg 13
Tashkent 13
Totale 17.662
Salva come PNG Salva come JPEG
Nome #
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma 233
Angiogenesis in adenosquamous cancer of pancreas 197
Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells 177
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 173
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 164
Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma 160
Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study 158
Targeting angiogenesis in biliary tract cancers: An open option 153
Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma 152
NHERF1 and tumor microenvironment: A new scene in invasive breast carcinoma 147
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 145
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 144
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma 144
Bone metastases in biliary cancers: A multicenter retrospective survey 143
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 142
Adjuvant colon cancer chemotherapy: Where we are and where we'll go 140
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 139
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 139
Anti-EGFR monoclonal antibody in cancer treatment: In vitro and in vivo evidence 139
Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity 137
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence 137
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 134
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 133
The European accreditation of Istituto Tumori Giovanni Paolo II of Bari 133
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 133
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 133
The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy 133
[Apoptosis or programmed cell death: regulatory and pathophysiological mechanisms]. FT Apoptosi, o morte cellulare programmata: meccanismi regolatori e fisiopatologia. 132
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 132
Adjuvant therapy in colon cancer 131
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 130
Natural history of bone metastasis in colorectal cancer: Final results of a large Italian bone metastases study 130
Prognostic role of high-grade tumor budding in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis with a focus on epithelial to mesenchymal transition 130
mTOR as a target of everolimus in refractory/relapsed Hodgkin Lymphoma 130
Carcinogenesis of pancreatic adenocarcinoma: Precursor lesions 129
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 129
Immunotherapeutic approaches for hepatocellular carcinoma 128
Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer 127
Should tumor infiltrating lymphocytes, androgen receptor, and FOXA1 expression predict the clinical outcome in triple negative breast cancer patients? 126
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity 125
IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity 124
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 124
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 124
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper 123
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 122
Challenges and opportunities of MicroRNAs in lymphomas 122
The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma 122
Metronomic chemotherapy from rationale to clinical studies: A dream or reality? 121
How to deal with second line dilemma in metastatic colorectal cancer? A systematic review and meta-analysis 121
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 121
Molecular classifications of gastric cancers: Novel insights and possible future applications 121
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 121
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 120
Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype 120
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 120
Co-expression of CD133+/CD44+ in human colon cancer and liver metastasis 119
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 119
Combined modality treatments in pancreatic cancer 119
Synthetic lethality to overcome cancer drug resistance 119
Antineoplastic drug-induced bradyarrhythmias 119
Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior? 118
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: From biological principles to clinical guidelines 118
Metastatic gastric cancer in the last two decades: Goals achieved and future promises 118
Target therapies in pancreatic carcinoma 118
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside 118
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib 116
p53 as the main traffic controller of the cell signaling network 116
HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives 115
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department 115
Current status of targeted therapies in advanced gastric cancer 114
Estimating survival probabilities of advanced gastric cancer patients in the second-line setting: The gastric life nomogram 113
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice 113
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 112
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 112
CES2, ABCG2, TS and topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen 112
Advances in EGFR-directed therapy in head and neck cancer 112
High density of tryptase-positive mast cells in human colorectal cancer: A poor prognostic factor related to protease-activated receptor 2 expression 111
A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer 111
Torch study: How much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer? 110
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 110
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 110
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma 110
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 110
Fas/Fas-ligand (Fas-L)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells 109
Immunotherapy for colorectal cancer: where are we heading? 109
Oncosuppressor methylation: A possible key role in colon metastatic progression 109
New molecular targets in bone metastases 109
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma 108
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 108
Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey 108
Actors on the scene: Immune cells in the myeloma niche 108
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 106
KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: An open issue 106
Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey 106
Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients. 105
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy 105
The process of truth disclosure: An assessment of the results of information during the diagnostic phase in patients with cancer 105
Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers 104
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX 104
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: A gruppo oncologico dell'Italia meridionale multicenter phase II study 103
Totale 12.586
Salva come PNG Salva come JPEG
Categoria #
all - tutte 123.461
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 123.461
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.677 0 0 0 0 0 330 206 254 217 285 266 119
2021/20222.210 158 210 40 77 159 151 111 133 142 113 227 689
2022/20233.704 403 517 292 362 319 414 111 475 541 26 204 40
2023/20241.173 84 216 80 103 124 324 19 66 9 28 10 110
2024/20254.596 96 83 364 208 154 517 390 427 163 224 742 1.228
2025/20265.130 1.508 411 608 847 1.292 464 0 0 0 0 0 0
Totale 24.709